

1 Potential hidden *Plasmodium vivax* malaria reservoirs from low 2 parasitemia Duffy-negative Ethiopians: molecular evidence 3

4 Abnet Abebe^{1,2*}, Isabelle Bouyssou^{3,4}, Solenne Mabilotte⁵, Sisay Dugassa¹, Ashenafi Assefa^{2,6},
5 Jonathan J. Juliano⁷, Eugenia Lo⁸, Didier Menard^{3,5,9,10}, Lemu Golassa^{1*}
6
7

8 Affiliations

9 ¹ Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Ethiopia.

10 ² Ethiopian Public Health Institute, Addis Ababa, Ethiopia.

11 ³ Institut Pasteur, Université Paris Cité, Malaria Genetics and Resistance Unit, INSERM U1201, F-75015
12 Paris, France.

13 ⁴ Sorbonne Université, Collège Doctoral ED 515 Complexité du Vivant, F-75015 Paris, France.

14 ⁵ Université de Strasbourg, Institute of Parasitology and Tropical Diseases, UR7292 Dynamics of Host-
15 Pathogen Interactions, F-67000 Strasbourg, France.

16 ⁶ Institute of Infectious Disease and Global Health, University of North Carolina at Chapel Hill, Chapel
17 Hill, NC, USA.

18 ⁷ Division of Infectious Disease, School of Medicine, University of North Carolina at Chapel Hill, Chapel
19 Hill, NC, USA.

20 ⁸ Department of Biological Sciences, Bioinformatics Research Center, University of North Carolina at
21 Charlotte, USA.

22 ⁹ Institut Pasteur, Université Paris Cité, Malaria Parasite Biology and Vaccines Unit, F-75015 Paris,
23 France.

24 ¹⁰ CHU Strasbourg, Laboratory of Parasitology and Medical Mycology, F-67000 Strasbourg,
25 France
26
27

28 *Corresponding authors; E-mail:

29 Abnet Abebe: abnetabas@gmail.com

30 Phone: +251911701745; P.O. Box 24756; Addis Ababa, Ethiopia

31 Lemu Golassa : lgolassa@gmail.com

32 Phone: +251911371981
33
34
35
36
37
38
39
40
41
42
43

44 **Abstract**

45 **Background:** The interaction between the *Plasmodium vivax* Duffy-binding protein and the
46 corresponding Duffy Antigen Receptor for Chemokines (DARC) is primarily responsible for the
47 invasion of reticulocytes by *P. vivax*. The Duffy-negative host phenotype, highly prevalent in
48 sub-Saharan Africa, is caused by a single point mutation in the GATA-1 transcription factor
49 binding site of the DARC gene promoter. The aim of this study was to assess the Duffy status of
50 patients with *P. vivax* infection from different study sites in Ethiopia.

51 **Methods:** A cross-sectional study was conducted from February 2021 to September 2022 at five
52 varying eco-epidemiological malaria endemic sites in Ethiopia. Outpatients who were diagnosed
53 with *P. vivax* infection (pure and mixed *P. vivax/P. falciparum*) by microscopy were subjected to
54 qPCR genotyping at the DARC promoter. The associations between *P. vivax* infection, host
55 genotypes and other factors were evaluated.

56 **Result:** In total, 361 patients with *P. vivax* infection were included in the study. Patients with
57 pure *P. vivax* infections accounted for 89.8% (324/361), while the remaining 10.2% (37/361) had
58 mixed *P. vivax/P. falciparum* infections. About 95.6% (345/361) of the participants were Duffy-
59 positives (21.2% homozygous and 78.8%, heterozygous) and 4.4% (16/361) were Duffy-
60 negatives. The mean asexual parasite density in homozygous and heterozygous Duffy-positives
61 was 12,165 p/μl (IQR25-75: 1,640-24,234 p/μl) and 11,655 p/μl (IQR25-75: 1,676-14,065 p/μl),
62 respectively, significantly higher than that in Duffy-negatives (1,227p/μl; IQR25-75: 539-
63 1,732p/μl).

64 **Conclusion:** This study confirms that Duffy-negativity does not provide complete protection
65 against *P. vivax* infection. The development of *P. vivax*-specific elimination strategies, including
66 alternative antimalarial vaccines should be facilitated by a better understanding of the

67 epidemiological landscape of *vivax* malaria in Africa. More importantly, low parasitemia
68 associated with *P. vivax* infections in Duffy-negative patients may represent hidden reservoirs of
69 transmission in Ethiopia.

70

71 **Key Words:** *Plasmodium vivax*, Duffy, heterozygous, homozygous, malaria, Ethiopia

72

73

74 **Author Summary**

75

76 *Plasmodium vivax* generally receives less attention than *P. falciparum* and was neglected in sub-
77 Saharan Africa. However, the characteristics of *P. vivax* infection in Duffy-negative individuals,
78 and the distribution of Duffy blood group in different eco-epidemiological zones and ethnic
79 groups of Ethiopia are not well documented. Here, we determined the Duffy genotypes of *P.*
80 *vivax* infected patients across broad regions of Ethiopia. It is clear that Duffy negative
81 individuals in Ethiopia are not fully protected against *P. vivax* infection, and that these infections
82 in Duffy negatives are often associated with low parasitemia. Our findings lend support to the
83 notion that *P. vivax* may have developed a Duffy-independent erythrocyte invasion pathway
84 and/or evolution in host immune responses.

85

86

87

88

89

90

91 **Introduction**

92
93 In 2021, there were an estimated 247 million cases and 619,000 deaths from malaria worldwide.

94 Of these, 2% of the cases were due to *P. vivax*, mainly in the Horn of Africa, South America,
95 India and Asia (1). *P. vivax* malaria is recognized as a cause of severe morbidity and mortality,
96 with a significant negative impact on health in endemic countries (2–4). The unique biological
97 features of *P. vivax*, such as hypnozoite formation and early gametocytogenesis, pose a challenge
98 to global malaria elimination efforts (5).

99 The *P. vivax* invasion pathway into reticulocytes was previously thought to be primarily
100 dependent on the interaction between the Duffy binding protein (PvDBP) and its cognate
101 receptor, the Duffy Antigen Receptor for Chemokines (*DARC*) (6–8). Polymorphisms in the
102 promoter of the *DARC* gene alter the expression of the Duffy antigen protein and determine an
103 individual's Duffy blood group (9). A point mutation in the GATA-1 transcription factor binding
104 site of the promoter of the gene at position–67 encodes the change of a T nucleotide to a C
105 nucleotide and underlies the Duffy-negative (erythrocyte silent) phenotype (10–12). Individuals
106 with this mutation do not express the Duffy antigen on the surface of their erythrocytes (13).
107 Duffy-negative phenotype in the population occurs at low frequency in Caucasians (~3.5%) (14),
108 and has a prevalence of almost 100% in West Africa, > 80% in African Americans (15), 20-36%
109 in East Africa and 84% in southern Africa (16). In Ethiopia, a study reported 94/416 (~23%) of
110 the febrile patients from the six health centres/hospitals were Duffy-negatives, though only two
111 of them were confirmed with *P. vivax* (17).

112 The scientific paradigm that *P. vivax* exclusively invades Duffy-positive reticulocytes through
113 the interactions of PvDBP and *DARC* was established, and it was assumed that *vivax* malaria was
114 rarely transmitted or even absent in regions where Duffy-negativity predominates, such as sub-

115 Saharan Africa (18,19). However, recent studies have shown that *P. vivax* can infect Duffy-
116 negative reticulocytes (20), and is no longer a barrier to such infections (21). In East Africa, the
117 prevalence of *P. vivax* in Duffy-negative populations ranges from 3% (22) to ~12% in
118 Ethiopia(16) and 3%(16) to ~18% in Sudan (9). Although several studies have demonstrated the
119 presence of *P. vivax* infection in Duffy-negative individuals, the distribution of these infections
120 in different eco-epidemiological zones and ethnic groups are not well documented, especially in
121 Ethiopia. This study compares the prevalence of Duffy blood group genotypes of *P. vivax*
122 infected patients among different eco-epidemiological zones of Ethiopia.

123

124 **Materials and Methods**


125 **Study design, period and areas**

126 A health-facility based cross-sectional study was conducted from February 2021 to September
127 2022. Based on the annual parasite index (API), malaria risk stratification in Ethiopia is divided
128 into five classes: i) malaria free, ii) very low, iii) low, iv) moderate and v) high malaria risk.

129 The study sites were selected from different malaria risk stratification areas. The sites include:
130 Arbaminch, Dubti, Gambella, Metehara, and Shewarobit (**Figure 1**). Arbaminch hospital is
131 located in the Southern Nation and Nationalities People Regional State in the southern part of the
132 country (altitude 1200 m; Lat, Long: 6.02043, 37.56788); Dubti hospital is located in the Afar
133 Regional State in the northern-east part of the country (altitude 379 m; Lat, Long: 11.72654,
134 41.09440); Gambella hospital is located in Gambella Regional State in the western part of the
135 country (altitude 447 m; Lat, Long: 8.24810, 34.59071); Metehara hospital is located in Oromia
136 Regional State in the eastern part of the country (altitude 959 m, Lat, Long: 8.89932, 39.91726);

137 and Shewarobit hospital is located in Amhara Regional State in the northern part of the country
138 (altitude 1268 m; Lat, Long: 10.01734, 39.91253).

139



140
141 **Figure 1. A map of the study sites with malaria risk stratification background, Ethiopia.**

142
143 **Sample collection**

144
145 Blood samples diagnosed positive for *P. vivax* (pure or mixed *P. vivax/P. falciparum*) by qPCR
146 from patients seen at health facilities were included to determine their Duffy status. The sample
147 size was calculated based on the proportion of Duffy-negative (20%) cases previously reported
148 in Ethiopia (23).

149

150 **Malaria diagnosis by Rapid Diagnostic Tests (RDT) and microscopy**

151 Finger prick blood samples were collected from self-reported febrile patients seeking malaria
152 diagnosis at a participating health centre. The malaria laboratory diagnosis was carried out for
153 each suspected malaria patient using RDT and microscopy. SD BIOLINE Malaria Ag *Pf/Pv*
154 (05FK80) RDT was used for the detection of HRP-II (Histidine-rich protein II) specific for *P.*
155 *falciparum* and *Plasmodium* lactate dehydrogenase (pLDH) specific for *P. vivax*. Five
156 microliters (5µl) of sample were obtained for the test and the result was interpreted after 15
157 minutes (up to 30 minutes) according to the manufacturer's guidelines.
158 Thick and thin blood films (stained with 10% Giemsa staining solution - pH 7.2 - for 10 minutes)
159 were prepared from finger-prick blood samples. Parasite densities were determined on thick
160 films by expert malaria microscopists for both sexual and asexual stages of the parasites,
161 considering a minimum of 200 WBCs, the reported number of parasites per microliter of blood,
162 assuming a total white blood cell count of 8000/µL. *P. vivax* sexual stages/gametocytes
163 quantification was performed on the blood film with *P. vivax* (pure) and a mixed species (*P.*
164 *vivax/P. falciparum*). Parasitemia was then classified as low (<1000 parasites per microliter of
165 blood), intermediate (1000-4999 parasites per microliter of blood) and high (≥5000 parasites per
166 microliter of blood) (24). Slides were declared negative after examination of at least 100 high-
167 power microscope fields (25). Blood film slides were re-examined and quantified by WHO
168 certified malaria microscopists. Patients who were positive for *P. vivax* (pure) and mixed *P.*
169 *vivax/P. falciparum* infection by both RDT and microscopy were included in the study. Venous
170 blood samples were collected and spotted onto Whatman™ 903 Protein Saver Card, US (Dried
171 Blood Spot, DBS), for molecular analysis of the Duffy genotypes.

172 **DNA extraction and molecular diagnosis of *Plasmodium* species**

173 Genomic DNA (human and parasite) was extracted from a 6 mm diameter spot of a DBS sample
174 and eluted in 100µl of TE Buffer (Tris-EDTA) using the QIAamp DNA Extraction Kit (Cat.No:
175 79216, Lot: 172018338, Germany) according to the manufacturer's instructions for the
176 molecular identification of malaria parasites and Duffy genotypes. The extracted DNA was
177 stored at -20°C for further use.

178 Primers previously designed to target the mitochondrial species-specific *cytochrome b* (*cytb*)
179 gene were used for the detection and identification of *P. vivax* and *P. falciparum* (**Table 1**).

180 Given the multiple copies of the mitochondria, this assay allows the detection of low density
181 *Plasmodium* infections in malaria pre-elimination settings (26).

182

183 **Table 1. Species-specific primers used for the detection and the species identification of *P.***
184 ***vivax* and *P. falciparum*.**

Species	Forward or Reverse	Primer
<i>P. vivax</i>	Forward	5'- TGCTACAGGTGCATCTCTTGTATTC -3'
	Reverse	5'- ATTTGTCCCCAAGGTAAAACG -3'
<i>P. falciparum</i>	Forward	5'- ATGGATATCTGGATTGATTTTATTTATGA -3'
	Reverse	5'- TCCTCCACATATCCAAATTACTGC -3'

185

186 The PCR amplifications were carried out using 10 µL of Advanced Mix Sybgreen (2x) (Catalog
187 # 1725271, Bio-Rad laboratories Inc. United State), 4 µL of water, 0.5 µL of each primer, and 5
188 µL of DNA template with the final volume of 20 µL in a Bio-Rad CFX96™ Real-Time PCR
189 detection system.

190

191 **Molecular Identification of the Duffy genotypes**

192 Molecular identification of the Duffy genotype was based on a novel sequence-specific PCR
193 primers (Amplification Refractory Mutation System, ARMS) that allows amplifications of the
194 GATA-1 transcription factor-binding site of the *DARC* gene promoter only when the target allele
195 (TCT for Duffy-positive and CCT for Duffy-negative genotypes) is detected in the sample.
196 Different sets of primers were designed and tested using Duffy-positive and Duffy-negative
197 DNA controls which were validated by PCR and Sanger sequencing (see **S1 Appendix A**) (27) to
198 detect the Duffy genotype by qPCR. The forward primers contain a nucleotide mismatch at the 3'
199 end (T for Duffy-positive and C for Duffy-negative genotypes) in addition to a mismatch base
200 near to the SNP at the 3' end (C for Duffy-positive and A for Duffy-negative genotypes), to
201 avoid false-amplification and prevent binding to non-complementary sequence and terminate
202 amplification. The reverse primer are the same (**Table 2**). All Duffy negative samples found by
203 PCR ARMS have been confirmed by Sanger sequencing.

204

205 **Table 2: AMRS PCR primers used for the detection of Duffy-positive and -negative genotypes.**

Duffy genotype	Forward or Reverse	Primer
positive	Forward	5' - CCCTCATTAGTCCTTGGCTCTCAT -3'
	Reverse	5' - CACCCTGTGCAGACAGTTCC -3'
negative	Forward	5' - CCCTCATTAGTCCTTGGCTCTAAC -3'
	Reverse	5' - CACCCTGTGCAGACAGTTCC -3'

206

207 Briefly, polymorphisms in the GATA-1 were detected in two separate real-time PCR reactions.
208 Real-time PCR reactions were performed with 10 µL of ssAdvanced mix sybgreen 2x, 10µM of
209 primers and 5 µL of DNA extract, and amplified on the CFX96 PCR instrument (Bio-Rad,
210 Marnes-la-Coquette, France). PCR amplification was carried out under the following conditions:
211 heating at 98 °C for 3 min, followed by 35 cycles of heating at 95 °C for 20 s, and of
212 annealing/extension at 62 °C for 30 s and a final extension step at 72°C for 10 min. After
213 completion of the amplification reaction, a melting curve (65-90°C) was generated to detect non-
214 specific PCR amplification. For each run, homozygous (TCT/TCT), heterozygous (TCT/CCT)
215 Duffy-positive, and homozygous Duffy-negative (CCT/CCT) samples were included as positive
216 controls and a no template (water) as negative control (see **S1 Appendix B**).

217

218 **Statistical analyses**

219 Data were analysed using Statistical Package for Social Sciences (SPSS, version 25). Chi-
220 squared, or Fisher's exact tests were used for frequency data (expressed as percentages).
221 Associations between Duffy genotypes and different variables were assessed using Fisher's exact
222 test. Two-sided p-values less than 0.05 were considered as statistically significant.

223

224 **Ethical statement**

225 Ethical approval was obtained from Akililu Lema Institute of Pathobiology Institutional Review
226 Board (IRB) (Ref No: ALIPB IRB/34/2013/20), Addis Ababa University, Addis Ababa,
227 Ethiopia. An official letter was sent to the study sites and the study was initiated after obtaining
228 permission from the respective health facilities. Written informed consent and/or assent was
229 obtained from all study participants, using the local language where appropriate.

230

231 **Results**

232 ***Characteristics of study participants.*** A total of 361 PCR-confirmed *P. vivax* (mono or mixed)
233 infected samples were included for the molecular analysis of Duffy status. Among them, 126
234 (34.9%) were female, the mean age was 25 years old (ranging from 1-80 years old), 108 (29.9%)
235 had no occupation, and 152 (42.1%) participants live in rural areas (***Table 3***).

236

237 ***Table 3. Sociodemographic characteristics of study participants in Ethiopia (n=361)***

Variables	Category	Number	Percent (%)
Gender	Female	126	34.9
	Male	235	65.1
Age stratification in years	≤14	40	11.1
	15-24	135	37.4
	25-34	122	33.8
	≥35	64	17.7
Ethnic	Amhara	106	29.4
	Anuak	13	3.6
	Somale	6	1.7
	Oromo	76	21.1
	Afar	52	14.4
	Tigre	11	3.0
	Welayita	30	8.3
	Gamo	37	10.2


	Sidama	11	3.0
	Hadiya	3	0.8
	Nuer	16	4.4
	Arbaminch	74	20.5
	Dubti	68	18.8
Study Sites	Gambella	74	20.5
	Metehara	75	20.8
	Shewarobit	70	19.4

238

239 Based on Duffy genotyping, 345 (95.6%) of the *P. vivax* patients were Duffy-positives (272

240 (78.8%) were heterozygous and 73 (21.2%) were homozygous) and 16 (4.4%) were Duffy-

241 negatives.



242

243

244 **Figure 2. Pie chart of Duffy status of study participants, Ethiopia (n=361)**


245

246 ***Distribution of the Duffy genotypes by study sites, study participants, ethnicity, gender, and***
247 ***age.***

248 Amongst the 361 samples tested, 73 (20.2%) were TCT/TCT, 272 (75.4%) were TCT/CCT and
249 16 (4.4%) were CCT/CCT. The Duffy-negative patients (CCT/CCT genotype) from Arbaminch,
250 Gambella, Metehara and Shewa robit was 2.7%, 8.1%, 4.0%, and 7.1%, respectively (**Figure 3**).
251 No Duffy-negatives were detected from Dubti. The highest proportion of Duffy-negatives was in
252 Gambella (8.1%, 6/74) and the lowest in Arbaminch (2.7%, 2/74). There was no significant
253 association between Duffy genotype and study site ($p=0.12$). The highest proportion of Duffy-
254 negatives was observed in the Nuer ethnic group (12.5%, 2/16) followed by the Agnuwak group
255 (7.7%, 1/13). No Duffy-negatives was identified among the Somale, Afar, Tigre, Welayita and
256 Hadiya ethnic groups. No significant association was found between Duffy genotype and ethnic
257 group ($p=0.50$). About 5.5% (13/235) male and 2.4% (3/126) female participants were Duffy-
258 negatives, with no significant association between Duffy genotype and gender ($p=0.16$). From
259 different age stratification(22), the lowest proportion of Duffy-negatives was identified from the
260 age groups ≤ 14 (2.5%, 1/40) and 25-34 (2.5%, 3/122), while the highest proportion was
261 identified from the age group ≥ 35 (7.8%, 5/64), no significant association between Duffy
262 genotype and age groups ($p=0.337$). (**Table 4**). Similarly, among the Duffy-positive
263 participants, the relative proportions of heterozygous and homozygous were not associated with
264 either study site ($p=0.47$), ethnic group ($p=0.47$) or gender ($p=0.17$) (**Table 5**).

265

266



267

268 **Figure 3. Map showing the distribution of the Duffy genotypes at five different malaria**
 269 **endemic sites in Ethiopia.**

270

271 **Table 4. Analysis of Duffy status by study sites (altitude), study participants ethnicity and**
 272 **gender (n=361)**

Variables	Duffy Status			Chi-Square	p-value	
	Positive	Negative	Total			
	n (%)	n (%)				
Study	Arbaminch(1200 m)	72 (97.3)	2 (2.7)	74	7.284	0.12

sites	Dubti (379 m)	68 (100)	0	68		
(altitude)	Gambella (447 m)	68 (91.9)	6 (8.1)	74		
	Metehara (959 m)	72 (96.0)	3 (4.0)	75		
	Shewarobit(1268 m)	65 (92.9)	5 (7.1)	70		
	Amhara	100 (94.3)	6 (5.7)	106		
Ethnic of Study participants	Agnuwak	12 (92.3)	1 (7.7)	13		
	Somale	6 (100)	0	6		
	Oromo	71 (93.4)	5 (6.6)	76		
	Afar	52 (100)	0	52		
	Tigre	11 (100)	0	11	9.313	0.50
	welayita	30 (100)	0	30		
	Gamo	35 (94.6)	2 (5.4)	37		
	Sidama	11 (100)	0 (0)	11		
	Hadiya	3 (100%)	0	3		
	Nuer	14 (87.5)	2 (12.5)	16		
Gender	Female	123 (97.6)	3(2.4)	126	1.923	0.16
	Male	222 (94.5)	13(5.5)	235		
Age in years	≤14	39(97.5%)	1 (2.5%)	40		
	15-24	128(94.8%)	7 (5.2%)	135	3.381	0.337
	25-34	119(97.5%)	3 (2.5%)	122		
	≥35	59 (92.2%)	5 (7.8%)	64		

274 **Table 5. Analysis of heterozygous and homozygous Duffy positive patients with study site**
 275 **(altitude), ethnicity, and gender (n = 312)**

Variables	Duffy Positive			Chi-Square	p-value	
	Homozygous	Heterozygous	Total			
	n (%)	n (%)				
Study Sites (altitude)	Arbaminch	20 (27.8)	52 (72.2)	72	3.546	0.47
	Dubti	12 (17.6)	56 (82.4)	68		
	Gambella	16 (23.5)	52 (76.5)	68		
	Metehara	12 (16.7)	60 (83.3)	72		
	Shewarobit	13 (20.0)	52 (80.0)	65		
Ethnicity of study participants	Amhara	20 (20.0)	80 (80.0)	100	9.608	0.47
	Agnuwak	4 (33.3)	8 (66.7)	12		
	Somale	0 (0.0)	6 (100)	6		
	Oromo	13 (18.3)	58 (81.7)	71		
	Afar	10 (19.2)	42 (80.8)	52		
	Tigre	2 (18.2)	9 (81.8)	11		
	welayita	7 (23.3)	23 (76.7)	30		
	Gamo	10 (28.6)	25 (71.4)	35		
	Sidama	5 (45.5)	6 (54.5)	11		
	Hadiya	0 (0)	3 (100)	3		
Nuer	2 (14.3)	12 (85.7)	14			
Gender	Female	31 (25.2)	92 (74.8)	123	1.874	0.17

	Male	42 (18.9)	180 (81.1)	222		
	≤14	4 (10.3%)	35 (89.7%)	39		
Age in years	15-24	31 (24.2%)	97 (75.8%)	128	3.801	0.284
	25-34	24 (20.2%)	95 (79.8%)	119		
	≥35	14 (23.7%)	45 (76.3%)	59		

276

277

278 ***Distribution of the Duffy genotype by P. vivax infections.***

279 For the 16 *P. vivax* infections in Duffy negatives, 12 (75%) were mono-infection and four (25%)
 280 were mixed *P. vivax/P. falciparum* infections. For the 345 *P. vivax* infections in Duffy positives,
 281 312 (90%) were mono-infections and 33 (~10%) were mixed *P. vivax/P. falciparum* infections.

282 The proportion of mixed *P. vivax/P. falciparum* infections was two-fold higher in Duffy-negative
 283 than in Duffy positive individuals ($p=0.047$), despite small samples for the Duffy negatives
 284 (**Table 6**). Of the 73 homozygous Duffy-positives, 68 (93.2%) were pure *P. vivax* infections and
 285 5 (6.8%) were mixed *P. vivax/P. falciparum* infections, slightly lower than that observed in
 286 heterozygous Duffy-positives of which 244 (78.2%) were pure *P. vivax* infections and 28
 287 (10.3%) were mixed *P. vivax/P. falciparum* infections ($p=0.37$) (**Table 6**).

288

289 ***Table 6. Analysis of P. vivax pure and mixed P. vivax/P. falciparum infections with Duffy***
 290 ***genotype (n=361).***

Variables	<i>P. vivax</i> infections			Chi-Square	P-value
	Pure n (%)	Mixed n (%)	Total		
Duffy positive	312 (90.4)	33 (9.6)	345	3.96	0.047

genotype	negative	12 (75)	4 (25)	16		
	Total	324 (89.8)	37 (10.2)	361		
Duffy Positive	homozygous	68 (93.2)	5 (6.8)	73	0.79	0.37
	heterozygous	244 (89.7)	28 (10.3)	272		
	Total	312 (90.4)	33 (9.6)	345		

291

292 ***Asexual and sexual parasitemia comparison by Duffy groups***

293 Of the samples with an asexual stage density of <1,000 p/μL and ranging from 1,000 to 4,999
 294 p/μL, 9/60 (15.0%) and 7/131 (5.3%) were obtained from Duffy-negative individuals,
 295 respectively. Interestingly, no Duffy-negatives were detected with asexual parasite density ≥5000
 296 p/μL but only Duffy positive patients (n=170; **Table 7**). The mean asexual parasite density in
 297 homozygous and heterozygous Duffy-positives was 12,165 p/μl (IQR25-75: 1,640-24,234 p/μl)
 298 and 11,655 p/μl (IQR25-75: 1,676-14,065 p/μl), respectively, significantly higher than that in
 299 Duffy-negatives (1,227 p/μl; IQR25-75: 539-1,732 p/μl) ($p < 0.001$; **Figure 4**).

300 Of the samples with a sexual gametocytemia of <1,000 p/μL, 8/180 (4.4%) were detected in
 301 Duffy-negative individuals (**Table 7**). The other eight *P. vivax* infections in Duffy negatives were
 302 detected with no gametocytes. By contrast, 172/180 (95.6%) of the Duffy-positives were
 303 detected with sexual gametocytemia of <1,000 p/μL, 31 were detected with gametocytemia of
 304 1,000-4999 p/μL, and 4 with gametocytemia of ≥5,000 p/μL.


305

306 ***Table 7. Association of Duffy status with asexual parasite density (n=361)***

Variables	Duffy Status			Chi-Square	p-value
	Positive	Negative	Total		

		n (%)	n (%)			
Asexual stage	<1000	51 (85.0)	9 (15.0)	60		
	1000-4999	124 (94.7)	7 (5.3)	131	23.96	<0.001
density	≥5000	170 (100)	0 (0)	170		

307
308
309



310
311
312
313
314
315
316
317

Key: *Fy+/+*; homozygous Duffy-positive, *Fy+/-*; Heterozygous Duffy-positive, *Fy-/-*; Duffy-negative

Figure 4: Box plot showing the distribution of asexual parasite density among identified Duffy status.

318

319 **Discussion**

320 We report here the association between 361 pure *P. vivax* and mixed *P. vivax/P. falciparum*
321 infections collected from five eco-epidemiological study sites in Ethiopia and the Duffy
322 genotype of the patients. We assessed malaria infection by qPCR and polymorphisms in the
323 GATA-1 promoter affecting Duffy status by a novel ARMS-PCR approach. Here, we observed
324 that the proportion of Duffy-negative (4.4%) among *P. vivax* infected patients was lower than
325 previous studies conducted in different countries; Madagascar (9.3%)(27), different parts of
326 Ethiopia (10.5–11.9%)(16), and Sudan 17.9% (9), but relatively higher than study reports such as
327 Ethiopia 2.9%(22), south-eastern Iran 1.3%(28), Brazilian Amazon 0.6%(18). Duffy blood
328 groups remain highly polymorphic between different populations (29). Historically, individuals
329 with the Duffy-negative phenotype were thought to be resistant to *P. vivax* infection (18,19,30–
330 32), but recent reports have shown *P. vivax* infection in Duffy-negative individuals (20,33–37) in
331 many parts of Africa.

332 This study identified 4.4% (16/361) *P. vivax* infections in Duffy-negative patients. This is
333 different from Central or West Africa, where the Duffy-negative genotype is much more
334 common and almost all *P. vivax* infections occur among Duffy-negative individuals (36,38,39),
335 despite relatively low number of *P. vivax* cases compared to East Africa. Several hypotheses
336 have been put forward to explain the change in the pattern of infection in Duffy-negative
337 individuals. One is a change in the host susceptibility, which in turn may drastically affect the
338 distribution of *P. vivax* (9) and another is that *P. vivax* may have evolved to adapt to a wider
339 range of hosts, environments, and highly competent transmission vectors in Africa (33).
340 Alternatively, *P. vivax* parasites may have developed alternative mechanisms to bind and invade

341 reticulocytes as other host cell receptors have been shown to be involved in erythrocyte invasion
342 (40).

343 Polymorphisms in Duffy blood group among different ethnic groups may contribute to
344 the changing epidemiology of *vivax* malaria in Africa (41). The Ethiopian population has a very
345 heterogeneous ethnic composition. Eleven different ethnic groups were included in this study
346 and the proportion of Duffy-negative and Duffy-positive varied between ethnic groups and study
347 sites. A high proportion of Duffy-negative samples were observed among the Nuer followed by
348 the Agnuwak ethnic groups, but no Duffy-negative was identified among the Somale, Afar,
349 Tigre, Welayita and Hadiya ethnic groups. Other studies have also showed variation of Duffy
350 genotype between ethnic groups. For example, in Sudan the Duffy-negative phenotype was
351 identified in 83% of Shagia and 77% of Manasir tribes (42); in Mauritania 54% of Moors were
352 Duffy-positives while only 2% of black ethnic groups were Duffy-positives (41); in Colombia
353 Duffy genotypes were significantly associated with ethnicity (43). These findings suggest that
354 ethnic groups may be genetically distinct, resulting in different levels of susceptibility to *P. vivax*
355 infection, in addition to different hypothesis such as *P. vivax* trains with a new capacity for
356 erythrocyte invasion(27), or use several receptor-ligand interactions to tightly bind erythrocytes
357 in the absence of a Duffy receptor(21).

358 Duffy-negatives with pure *P. vivax* and mixed *P. vivax/P. falciparum* infections was
359 identified in the current study. The proportion of mixed *P. vivax/P. falciparum* infections in
360 Duffy-negative was 25% in the present study, which was similar with the findings from Nigeria
361 (25%)(45), and Cameroon (25%)(44), while it was lower than the study conducted in
362 Madagascar (26.7%)(46), and Democratic Republic of the Congo (64%)(38). The results provide

363 evidence that Duffy-negative individuals can be infected by pure *P. vivax* alone or together with
364 *P. falciparum*.

365 The mean asexual parasite density among Duffy-negatives (CCT/CCT) was 1,227 p/μl,
366 around tenfold lower compared to homozygous Duffy-positives (TCT/TCT; 12,165 p/μl) and
367 heterozygous Duffy-positive (TCT/CCT; 11,655 p/μl). Several prior studies have shown that *P.*
368 *vivax* infections observed in Duffy-negatives have a significantly lower parasitemia than in
369 Duffy-positive infections and are asymptomatic (13)(16). The low parasite densities found in
370 Duffy-negative malaria patients may indicate that *P. vivax* uses an alternative pathway to invade
371 Duffy-negative reticulocytes, which can be much less efficient than the classical pathway
372 involving the interaction between PvDBP and *DARC* (22). Alternatively, it has been
373 hypothesized that the reticulocytes of Duffy-negative individuals may express the *DARC* protein
374 in a transient and weak manner, thereby mediating a low invasion capacity (16). Among the 16
375 Duffy negative samples detected in this study, half were detected with low-level gametocytes.
376 The presence of gametocytes among Duffy negatives may further imply that these infections
377 have the potential contributing to onward transmission.

378 To conclude, this study reports heterogeneous proportions of Duffy-negative individuals
379 among *P. vivax* malaria patients across Ethiopia, confirms that Duffy-negativity does not provide
380 complete protection against *P. vivax* infection, and these infections are often associated with low
381 parasitemia, which may represent hidden reservoirs that can contribute to transmission.
382 Therefore, the development of *P. vivax*-specific elimination strategies, including alternative
383 antimalarial vaccines other than a Duffy-binding protein-based vaccine, should be facilitated by
384 a better understanding of the relationship between Duffy-negativity and the invasion mechanisms
385 of *P. vivax*.

386

387 **Abbreviations**

388 ALIPB: Aklilu Lema Institute of Pathobiology; *DARC*: Duffy antigen receptor for chemokines;
389 DBP: Duffy Binding Protein; DBS: Dried Blood Spots; DNA: Deoxyribonucleic Acid; EPHI:
390 Ethiopian Public Health Institute; HRP: Histidine-rich protein; IRB: Institutional Review Board;
391 MoE: Ministry of Education; NSP: National Strategic Plan; pLDH: *Plasmodium* lactate
392 dehydrogenase; *Pv/Pf*: *Plasmodium vivax* and *Plasmodium falciparum*; RDT: Rapid Diagnostic
393 Tests; RT PCR: Real Time Polymerase Chain Reaction; SNP: Single Nucleotide Polymorphism;
394 SOP: Standard Operating Procedures; SPSS: Statistical Package for Social Sciences; WBC:
395 White Blood Cells; WHO: World Health Organization

396

397 **Acknowledgements**

398 This work was supported by i) SIDA project, ii) Human, Heredity and Health in Africa
399 (H3Africa) [H3A-18-002]. H3Africa is managed by the Science for Africa Foundation (SFA
400 Foundation) in partnership with Wellcome, NIH and AfSHG and iii) the Institute Pasteur, Paris,
401 the University of Strasbourg, and the French Government (Agence Nationale de la Recherche;
402 ANR- 18-CE15-0026, ANR-21-CE35-0006 and the Laboratoire d'Excellence 'French
403 Parasitology Alliance for Health Care', ANR-11-15 LABX-0024-PARAFRAP), and iv) EPHI.
404 We would like to thank all the individuals who contributed technically to this study: the
405 laboratory staff at the study sites, the staff at ALIPB (parasitology department), the staff at the
406 Institute of Parasitology and Tropical Diseases, University of Strasbourg (Cécile Doderer-Lang),
407 and the statisticians (Dereje Dilu, Abriham Keraleme and Chalie). We must express our sincere

408 gratitude to all the regional health offices and the study sites for their cooperation. Last but not
409 least, our sincere thanks go to all the participants who took part in this study.

410

411 **Authors Contribution**

412 AA: Abnet Abebe, IB: Isabelle Bouyssou, SM: Solenne Mabilotte, SD: Sisay Dugassa, AA2:

413 Ashenafi Assefa, JJ: Jonathan Juliano, DM: Didier Menard, LG: Lemu Golassa

414

415 Conceptualization and Design: AA, LG

416 Drafting Proposal: AA

417 Revision: AA, LG, DM, SD, AA2, JJ

418 Data Collection: AA, LG, AA2, SD

419 Laboratory analysis: AA, IB, SM, DM, LG

420 Validation: AA, LG, DM, SD, AA2, JJ

421 Writing manuscript – draft: AA

422 Writing manuscript– review & editing: AA, LG, DM, SD, AA2, JJ

423

424

425

426

427

428

429

430 **References**

431

- 432 1. World Health Organization (WHO). World Malaria Report 2022.
433 <https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022>.
- 434 2. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, et al.
435 Vivax malaria: A major cause of morbidity in early infancy. *Clinical Infectious Diseases*.
436 2009;48(12):1704–12.
- 437 3. Kevin Baird J. Evidence and implications of mortality associated with acute plasmodium
438 vivax malaria. *Clinical Microbiology Reviews*. 2013;26(1):36–57.
- 439 4. Moreira CM, Abo-Shehada M, Price RN, Drakeley CJ. A systematic review of sub-
440 microscopic Plasmodium vivax infection. *Malaria Journal*. 2015;14(1):1–10.
- 441 5. Abebe A, Golassa L, Janies DA, Yewhalaw D, Lo E. Gene Polymorphisms Among
442 Plasmodium vivax Geographical Isolates and the Potential as New Biomarkers for
443 Gametocyte Detection. 2022;11(January):1–12.
- 444 6. Asok Caudhurit, Julia Polyakovat, Valerea Zbrzenat, Kennett William, Subhash Gulati
445 Pogo OA. Cloning of glycoprotein D cDNA, which encodes the major subunit of the
446 Duffy blood group system and the receptor for the Plasmodium vivax malaria parasite.
447 *Proc Natl Acad Sci USA*. 1993;90:10793–10797.
- 448 7. Tournamille C, Colin Y, Cartron JP, Le Van Kim C. “Disruption of a GATA motif in the
449 Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals.”
450 *Nat Genet*. 1995;10(2):224–8.
- 451 8. Howes RE, Patil AP, Piel FB, Nyangiri OA, Kabaria CW, Gething PW, et al. The global
452 distribution of the Duffy blood group. *Nat Commun*. 2011;2(4):266.

- 453 9. Musab MA, Albsheer KP, Safaa A, Mohammed E, Eiman G, Salma MA E al. Distribution
454 of Duffy Phenotypes among Plasmodium vivax Infections in Sudan. *Genes*. 2019;10:417.
- 455 10. Popovici J, Roesch C, Rougeron V. The enigmatic mechanisms by which Plasmodium
456 vivax infects Duffy-negative individuals. *PLoS Pathog*. 2020;16(2):e1008258.
- 457 11. Kepple D, Pestana K, Tomida J, Abebe A, Golassa L, Lo E. Alternative invasion
458 mechanisms and host immune response to Plasmodium vivax malaria: Trends and future
459 directions. *Microorganisms*. 2021;9(1):1–17.
- 460 12. Daniels G. The molecular genetics of blood group polymorphism. *Transplant*
461 *Immunology*. 2005;14(3-4 SPEC. ISS.):143–53.
- 462 13. Gunalan K, Niangaly A, Thera MA, Doumbo OK, Miller LH. Plasmodium vivax
463 Infections of Duffy-Negative Erythrocytes: Historically Undetected or a Recent
464 Adaptation? *Trends in Parasitology*. 2018;34(5):420–9. Available from:
465 <http://dx.doi.org/10.1016/j.pt.2018.02.006>
- 466 14. Yazdanbakhsh K, Rios M, Storry JR, Kosower N, Parasol N, Chaudhuri A, et A.
467 Molecular mechanisms that lead to reduced expression of duffy antigens. *Transfusion*.
468 2000;40(3):310–20.
- 469 15. Schmid P, Ravenell KR, Sheldon SL FW. DARC alleles and Duffy phenotypes in African
470 Americans. *Transfusion*. 2012;52:1260–7.
- 471 16. Loa E, Gianluca Russob, Pestanaa K, Kepplea D, Abageroc BR, Ghyslaine Bruna, et A.
472 Contrasting epidemiology and genetic variation of Plasmodium vivax infecting Duffy-
473 negative individuals across Africa. *International Journal of Infectious Diseases*.
474 2021;108:63–71.
- 475 17. Lo E, Yewhalaw D, Zhong D, Zemene E, Degefa T, Tushune K. Molecular epidemiology

- 476 of *Plasmodium vivax* and *Plasmodium falciparum* malaria among Duffy-positive and
477 Duffy-negative populations in Ethiopia. *Malaria Journal*. 2015;14(84).
- 478 18. Carlos EC, Luiz CM, Álvaro AR, D’Almeida C, Vanja SC, Yuri G, et al. Duffy blood
479 group gene polymorphisms among malaria vivax patients in four areas of the Brazilian
480 Amazon region. *Malaria Journal*. 2007;6:167.
- 481 19. Roesch C, Id JP, Bin S, Run V, Kim S, Rakotomalala E, et al. Genetic diversity in two
482 *Plasmodium vivax* protein ligands for reticulocyte invasion. 2018;1–17.
- 483 20. Mendes C, Dias F, Figueiredo J, Mora VG, Cano J, de Sousa B, et al. Duffy Negative
484 Antigen Is No Longer a Barrier to *Plasmodium vivax* – Molecular Evidences from the
485 African West Coast (Angola and Equatorial Guinea). *PLoS Negl Trop Dis*.
486 2011;5(6):e1192.
- 487 21. Wilairatana P, Masangkay FR, Kotepui KU, Milanez GDJ, Kotepui M. Prevalence and
488 risk of *Plasmodium vivax* infection among Duffy - negative individuals : a systematic
489 review and meta - analysis. *Scientific Reports*. 2022;1–13. Available from:
490 <https://doi.org/10.1038/s41598-022-07711-5>
- 491 22. Abate A, Bouyssou I, Mabilotte S, Lang CD, Dembele L, Menard D, et al. Vivax malaria
492 in Duffy - negative patients shows invariably low asexual parasitaemia : implication
493 towards malaria control in Ethiopia. *Malaria Journal*. 2022;1–10. Available from:
494 <https://doi.org/10.1186/s12936-022-04250-2>
- 495 23. Tamirat Gebru Woldearegai, Peter G. Kreamsner, Jürgen F. J. Kun BM. *Plasmodium vivax*
496 malaria in Duffy-negative individuals from Ethiopia. *Transactions of The Royal Society*
497 *of Tropical Medicine and Hygiene*. 2013;107(5):328–31.
- 498 24. Debash H, Bisetegn H, Ebrahim H, Feleke DG, Gedefie A, Tilahun M, et al. Prevalence

- 499 and associated risk factors of malaria among febrile under-five children visiting health
500 facilities in Ziquala district, Northeast Ethiopia: A multicenter cross-sectional study. PLoS
501 ONE. 2022;17(10 October):1–13. Available from:
502 <http://dx.doi.org/10.1371/journal.pone.0276899>
- 503 25. Nicholas D, Julie S, Aung P, Hadjar S, Armedy H, Enny K, et A. Gametocyte Dynamics
504 and the Role of Drugs in Reducing the Transmission Potential of Plasmodium vivax. JID.
505 2013;208:802–12.
- 506 26. Canier L, Khim N, Kim S, Sluydts V, Heng S, Dourng D, et al. An innovative tool for
507 moving malaria PCR detection of parasite reservoir into the field. Malaria Journal.
508 2013;12(1):1–12.
- 509 27. Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbaoa A, et A.
510 Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy
511 people. Proc Natl Acad Sci USA. 2010;107(13):5967–71.
- 512 28. Miri-moghaddam E, Bameri Z, Mohamadi M. Duffy blood group genotypes among
513 malaria Plasmodium vivax patients of Baoulch population in southeastern Iran. Asian
514 Pacific Journal of Tropical Medicine. 2014;7(3):206–7. Available from:
515 [http://dx.doi.org/10.1016/S1995-7645\(14\)60021-3](http://dx.doi.org/10.1016/S1995-7645(14)60021-3)
- 516 29. Ewa Ł, Nowak I, Czerwinski M, Wa K. Duffy blood group system – the frequency of Du
517 ff y antigen polymorphisms and novel mutations in the Polish population.
518 2019;(December 2018).
- 519 30. Guerra CA, Howes RE, Patil AP, Gething PW, van Boeckel TP, Temperley WH, et al.
520 The international limits and population at risk of Plasmodium vivax transmission in 2009.
521 PLoS Neglected Tropical Diseases. 2010;4(8).

- 522 31. Miller LH, Mason SJ, Clyde DF MM. The resistance factor to *Plasmodium vivax* in
523 blacks: the Duffy-blood-group genotype, FyFy. *N Engl J Med*. 1976;295:302–4.
- 524 32. Rondônia D, Brasileira AO, Cavasini CE, José F, Pereira T, Ribeiro WL, et al. Duffy
525 blood group genotypes among malaria patients in Rondônia , Western Brazilian Amazon
526 Genótipos do sistema sanguíneo Duffy em pacientes maláricos. 2001;34(6):591–5.
- 527 33. Abdelraheem MH, Albsheer MMA, Mohamed HS, Amin M, Hamid MMA. Transmission
528 of *Plasmodium vivax* in Duffy-negative individuals in central Sudan. *Transactions of the*
529 *Royal Society of Tropical Medicine and Hygiene*. 2016;110(4):258–60.
- 530 34. Zimmerman PA. *Plasmodium vivax* infection in Duffy-Negative People in Africa. *Am J*
531 *Trop Med Hyg*. 2017;97.
- 532 35. Dongho GBD, Gunalan K, L’Episcopia M, Paganotti GM, Menegon M, Sangong RE, et
533 al. *Plasmodium vivax* Infections Detected in a Large Number of Febrile Duffy-Negative
534 Africans in Dschang, Cameroon. *American Journal of Tropical Medicine and Hygiene*.
535 2021;104(3):987–92.
- 536 36. Oboh MA, Badiane AS, Ntadom G, Ndiaye YD, Diongue K, Diallo MA, et al. Molecular
537 identification of *Plasmodium* species responsible for malaria reveals *Plasmodium vivax*
538 isolates in Duffy negative individuals from southwestern Nigeria. *Malaria Journal*.
539 2018;17(1):1–12. Available from: <https://doi.org/10.1186/s12936-018-2588-7>
- 540 37. Ryan JR, Stoute JA, Amon J, Dunton RF, Mtalib R, Koros J, et al. Evidence for
541 transmission of *Plasmodium vivax* among a Duffy antigen negative population in Western
542 Kenya. *American Journal of Tropical Medicine and Hygiene*. 2006;75(4):575–81.
- 543 38. Brazeau NF, Whitesell AN, Doctor SM, Keeler C, Mwandagalirwa MK, Tshetu AK, et al.
544 *Plasmodium vivax* infections in duffy-negative individuals in the democratic republic of

- 545 the Congo. *American Journal of Tropical Medicine and Hygiene*. 2018;99(5):1128–33.
- 546 39. Poirier P, Doderer-Lang C, Atchade PS, Lemoine JP, De L’Isle MLC, Abou-Bacar A, et
547 al. The hide and seek of *Plasmodium vivax* in West Africa: Report from a large-scale
548 study in Beninese asymptomatic subjects. *Malaria Journal*. 2016;15(1):1–9.
- 549 40. Gruszczyk J, Kanjee U, Chan LJ, Menant S, Malleret B, Lim NTY, et al. Transferrin
550 receptor 1 is a reticulocyte-specific receptor for *Plasmodium vivax*. *Science*.
551 2018;359(6371):48–55.
- 552 41. Wurtz N, Mint Lekweiry K, Bogreau H, Pradines B, Rogier C, Ould Mohamed Salem
553 Boukhary A, et al. *Vivax malaria* in Mauritania includes infection of a Duffy-negative
554 individual. *Malaria Journal*. 2011;10:1–8.
- 555 42. Kempf A, Knap O, Drozd A, Kaczmarczyk M, Parafiniuk M. Analysis for genotyping
556 Duffy blood group in inhabitants of Sudan , the Fourth Cataract of the Nile. 2012;1–6.
- 557 43. Gonzalez L, Veg J, Ramirez Jose L, Bedoya G C-F. Relationship between Duffy blood
558 groups genotypes and malaria infection in different ethnic groups of Choco- Colombia.
559 *Colomb Med [online]* 2012, vol43, n3, pp189-195. 2012;43(3):189–95.
- 560 44. Gaelle H, Mbenda N, Das A. Molecular Evidence of *Plasmodium vivax* Mono and Mixed
561 Malaria Parasite Infections in Duffy-Negative Native Cameroonians. 2014;9(8):1–9.
- 562 45. Oboh MA, Singh US, Ndiaye D, Badiane AS, Ali NA, Bharti PK, et al. Presence of
563 additional *Plasmodium vivax* malaria in Duffy negative individuals from Southwestern
564 Nigeria. *Malaria Journal*. 2020;1–8. Available from: [https://doi.org/10.1186/s12936-020-](https://doi.org/10.1186/s12936-020-03301-w)
565 03301-w
- 566 46. Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbao A, et al.
567 *Plasmodium vivax* clinical malaria is commonly observed in Duffy-negative Malagasy

568 people. Proceedings of the National Academy of Sciences of the United States of
569 America. 2010;107(13):5967–71.

570

571

572

573 **Supporting information**

574

575 *Appendix A: Figures summarizing Sanger sequencing data*

576 *Appendix B: Figures summarizing AMRS PCR-based allelic discrimination amplification*
577 *curves in a control samples validated by PCR/Sanger sequencing*

578